NovaBay Pharmaceuticals, Inc.
NBYNovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative treatments for infections and skin conditions. The company is known for its research on novel antimicrobial compounds, particularly NVC-422, targeting ocular, skin, and mucous membrane infections. NovaBay aims to provide alternatives to traditional antibiotics, with a focus on anti-infective and dermatological products.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| September 29, 2025 | $0.80 | 2025-09-30 | 2025-09-15 |
Dividends Summary
- Consistent Payer: NovaBay Pharmaceuticals, Inc. has rewarded shareholders with 1 dividend payments over the past 0 years.
- Total Returned Value: Investors who held NBY shares during this period received a total of $0.80 per share in dividend income.
- Latest Payout: The most recent dividend of $0.80/share was paid 116 days ago, on September 29, 2025.
Company News
Multiple health care stocks experienced significant price movements during Monday's after-market trading session, with some companies seeing notable gains while others experienced declines.
NovaBay Pharmaceuticals announced a $0.80 per share special cash dividend payable on September 29, 2025, and will hold its annual stockholder meeting on October 16, 2025. The company is exploring strategic alternatives and remains optimistic about its future.
The global impetigo drugs market is expected to grow at a CAGR of 4.5% from 2023 to 2030, driven by factors such as the increasing incidence of impetigo, technological advancements in drug delivery, and the development of new antibiotics to combat antibiotic resistance.
NovaBay Pharmaceuticals is offering a 20% discount on its Avenova-branded eyecare products during Amazon Prime Day, aligning with National Dry Eye Awareness Month. The company aims to attract new and existing customers through this promotion, which comes amid growing sales of its products through online channels.
NovaBay Pharmaceuticals reported a 9% increase in net revenue for its eyecare segment in the second quarter and first half of 2024, driven by strong sales of its Avenova-branded products through online channels.
